Please note that eDoc will be permanently shut down in the first quarter of 2021!      Home News About Us Contact Contributors Disclaimer Privacy Policy Help FAQ

Home
Search
Quick Search
Advanced
Fulltext
Browse
Collections
Persons
My eDoc
Session History
Login
Name:
Password:
Documentation
Help
Support Wiki
Direct access to
document ID:


          Institute: MPI für experimentelle Medizin     Collection: Molecular Neuroendocrinology     Display Documents



  history
ID: 42783.0, MPI für experimentelle Medizin / Molecular Neuroendocrinology
Selective 5-HT1A antagonists WAY 100635 and NAD-299 attenuate the impairment of passive avoidance caused by scopolamine in the rat
Authors:Misane, Ilga; Ögren, Sven Ove
Language:English
Date of Publication (YYYY-MM-DD):2003-02
Title of Journal:Neuropsychopharmacology
Journal Abbrev.:Neuropsychopharmacology
Volume:28
Issue / Number:2
Start Page:253
End Page:264
Review Status:Peer-review
Audience:Experts Only
Abstract / Description:Systemic administration of the muscarinic-receptor antagonists atropine and scopolamine produces cognitive deficits in humans, nonhuman primates and rodents. In humans, these deficits resemble symptoms of dementia seen in Alzheimer's disease. The passive avoidance (PA) task has been one of the most frequently used animal models for studying cholinergic mechanisms in learning and memory. The present study examined the ability of two selective 5-HT1A receptor antagonists WAY 100635 and NAD- 299 (robalzotan) and two acetylcholinesterase (ACNE) inhibitors tacrine and donepezil to attenuate the impairment of PA retention caused by the nonselective muscarinic receptor antagonist scopolamine in the rat. Although demonstrating differences in their temporal kinetics, both WAY 100635 and NAD-299 attenuated the impairment of PA caused by scopolamine (0.3 mg/kg s.c.). Donepezil did not block the PA deficit caused by the 0.3 mg/kg dose of scopolamine, but it prevented the inhibitory effects of the 0.2 mg/kg dose of scopolamine. In contrast, tacrine was effective vs both the 0.2 and 0.3 mg/kg doses of scopolamine. These results indicate that (I) a functional 5-HT1A receptor antagonism can attenuate the anterograde amnesia produced by muscarinic-receptor blockade, and (2) the ACNE inhibitor tacrine and donepezil differ in their ability to modify muscarinic-receptor-mediated function in vivo. These results suggest that 5-HT1A receptor antagonists may have a potential in the treatment of cognitive symptoms in psychopathologies characterized by reduced ACh transmission such as Alzheimer's disease.
Free Keywords:passive avoidance; 5-HT1A receptors; muscarinic receptors; acetylcholinesterase inhibitors
Comment of the Author/Creator:Date: 2003, FEB
External Publication Status:published
Document Type:Article
Communicated by:Joachim Spiess
Affiliations:MPI für experimentelle Medizin/Molecular Neuroendocrinology
External Affiliations:Karolinska Inst, Dept Neurosci, Div Behav Neurosci, SE-17177; Stockholm, Sweden; Karolinska Inst, Dept Neurosci, Div Behav Neurosci, SE-17177 Stockholm, Sweden;
Identifiers:ISI:000181233300007 [ID No:1]
ISSN:0893-133X [ID No:2]
The scope and number of records on eDoc is subject to the collection policies defined by each institute - see "info" button in the collection browse view.